Two acute cases of liver disease in healthy subjects kill Arbutus' hep B program
In a significant setback, Vivek Ramaswamy-backed Arbutus Biopharma is ceasing the development of its experimental hepatitis B therapy, after two healthy volunteers contracted serious liver infection in an early-stage trial.
The therapy, AB-506, is an oral hepatitis B virus (HBV) capsid inhibitor designed to thwart viral reproduction, versus existing standard therapies — primarily nucleoside analogues — that are designed to diminish viral replication.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.